{"url_path":"/sec/traw/8-k/2026-07-09/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-082250-index.html","accession_number":"0001104659-26-082250","cik":"0001130598","ticker":"TRAW","issuer_name":"Traws Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-082250-index.html","primary_entity_key":"0001130598","primary_entity_name":"Traws Pharma, Inc."},"word_count":631,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote\nof Security Holders.**\n\n \n\nOn July 8, 2026, the\nCompany held the Annual Meeting in a virtual format. At the close of business on May 18, 2026, the record date for the Annual Meeting,\nthere were 15,150,669 shares of Company common stock issued and outstanding, which constituted all of the issued and outstanding shares\nof capital stock of the Company entitled to vote at the Annual Meeting. Pursuant to Nasdaq listing rules, holders of outstanding shares\nof the Company’s common stock, as of the Record Date, which were issued to certain investors pursuant to that certain Securities\nPurchase Agreement entered into by and between us and such investors on April 15, 2026, were not entitled to vote such shares on Proposal\nNo. 4 presented to stockholders for approval at the Annual Meeting. At the Annual Meeting, 8,452,410 of the Company’s 15,150,669\noutstanding shares of common stock entitled to vote as of the record date, or approximately 55.78%, were represented by proxy or in person\n(virtually), and, therefore, a quorum was present.\n\n \n\nThe proposals voted\non at the Annual Meeting are more fully described in the Proxy Statement, which information is incorporated herein by reference.\n\n \n\nThe final voting results\non the proposals presented for stockholder approval at the Annual Meeting were as follows:\n\n \n\n**Proposal 1:** To\nelect seven directors, each to hold office until our 2027 Annual Meeting of Stockholders and until his or her successor is elected and\nqualified. Each nominee for director was elected by a vote of the stockholders as follows:\n\n \n\n**Nominee**\n \n**Votes For**\n \n**Withheld**\n \n**Broker Non-Votes**\n\nIain Dukes, D.Phil.\n \n6,448,795\n \n73,766\n \n1,929,849\n\nWerner Cautreels, Ph.D.\n \n6,448,941\n \n73,620\n \n1,929,849\n\nTrafford Clarke, Ph.D.\n \n5,711,434\n \n811,127\n \n1,929,849\n\nJohn Leaman, M.D.\n \n6,466,029\n \n56,532\n \n1,929,849\n\nNikolay Savchuck Ph.D.\n \n6,448,282\n \n74,279\n \n1,929,849\n\nM. Teresa Shoemaker\n \n5,710,047\n \n812,514\n \n1,929,849\n\nJack E. Stover\n \n5,694,085\n \n828,476\n \n1,929,849\n\n \n\n**Proposal 2:** To\nconsider and vote upon an amendment of the Company’s 2021 Incentive Compensation Plan, as amended and restated, to increase the\nnumber of shares of common stock available for issuance by 2,000,000 and make certain other administrative changes. The proposal to approve\nthe Amended Plan was approved by a vote of the stockholders as follows:\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n4,821,796\n \n1,694,075\n \n6,690\n \n1,929,849\n\n \n\n \n\n \n\n \n\n**Proposal 3:** To\nconsider and vote upon the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal\nyear ending December 31, 2026. The proposal was approved by a vote of the stockholders as follows:\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n7,659,805\n \n789,757\n \n2,848\n \n0\n\n \n\n**Proposal 4:** To\napprove, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock upon exercise of those Series B\nWarrants and Series C Warrants to purchase shares of our common stock issued to certain investors pursuant to that certain Securities\nPurchase Agreement entered into by and between us and such investors on April 15, 2026. The proposal was approved by a vote of the\nstockholders as follows:\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n2,270,414\n \n151,196\n \n614,528*\n \n1,929,849\n\n \n\n*****As noted above,\nexcludes an aggregate of 3,486,423 shares from Proposal No. 4, in accordance with Nasdaq listing rules.\n\n \n\n**Proposal 5:** To\napprove the adjournment of the Annual Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional\nproxies in the event we have not received sufficient votes in favor of any of the foregoing proposals. The proposal was approved by a\nvote of the stockholders as follows:\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n7,882,130\n \n562,323\n \n7,957\n \n0\n\n \n\nAlthough Proposal 5\nwas approved by the Company’s stockholders, the Company did not elect to adjourn the Annual Meeting, as each of Proposals 1 through\n4 were approved by the Company’s stockholders."}